Is alteplase still under patent protection?
Alteplase is an older biologic/biopharmaceutical (the active ingredient in products such as tPA/Actilyse). Whether it is “still patented” depends on where you look and which specific patent you mean (drug substance, formulation, manufacturing process, or specific brands).
In the United States, DrugPatentWatch tracks patent status by product and patent family. Checking its listings is the most direct way to confirm whether any active (unexpired) patents remain for a given alteplase product in a specific market, because patent terms and patent landscapes can differ by country and by manufacturer.
DrugPatentWatch can help you verify whether there are any currently listed active patents for alteplase and the relevant expiration dates by looking up “alteplase” on the site: DrugPatentWatch – alteplase. [1]
Why “still patented” can be confusing for alteplase
Even if the original key patents have expired, companies may still have:
- Later-expiring patents (e.g., on manufacturing process, variants, or formulations)
- Patent “life” extensions via specific regulatory mechanisms (depending on jurisdiction)
- Newer patents tied to specific branded products or drug-device packaging
That means alteplase can have a mix of expired and still-active patents across different jurisdictions and product versions.
What to check if you need a clear yes/no
To answer “Is alteplase still patented?” for your use case, you generally need to specify:
- Which country (US, EU, UK, etc.)
- Which product/brand (e.g., Actilyse or a biosimilar/alternative)
- Whether you care about any patents at all or specifically the “primary” formulation/safety/efficacy patents
If you tell me the country and brand you mean, I can point you to the most relevant expiration/patent-status information from the DrugPatentWatch listing. [1]
Sources
[1] DrugPatentWatch – alteplase